Innovations in Oncology
Accord Healthcare’s Executive Vice President Paul Tredwell sat down with Mark Nicholls to discuss how important it is that the pharmaceutical industry listens to patients to best tailor innovation to their needs.
Paul outlines Accord’s expertise and ongoing commitment to oncology and some of the exciting plans underway in the UK, always driven by the Accord's ambition to ‘make it better’.
See his interview in the latest edition of Innovations in Oncology issued in today’s The Guardian newspaper.
#oncology #innovation #innovationsinoncology2022 #patients #pharmaceuticals #makeitbetter
Accord Healthcare has been nominated as a finalist in seven categories in the Global Generics & Biosimilars 2022 Awards.
Paul Tredwell, EVP EMENA says: “To be finalists in several categories at such a highly respected awards event is a testament to our people whose loyalty, drive and dedication to the healthcare industry go above and beyond our purpose.
“We look forward to the awards evening in November and congratulate all the other finalists.”
Accord Healthcare are finalists in the following categories: Company of the Year Company of the Year, EMEA Region Biosimilar Initiative of the Year Business Development of the Year Value Added Medicine Initiative of the Year Corporate Social Responsibility (CSR) Initiative of the Year Regulatory Achievement of the Year
The Times - Future of Pharma Supplement
Our support doesn’t have to stop at chemotherapy” says Joe Dunford as part of a Q&A feature in today’s The Times discussing the Future of Pharma.
Click to read
Click to read
Accord Healthcare featured in The Guardian
Accord Healthcare’s Joseph Dunford and Simon Cheesman are featured in today’s Men’s Health supplement of The Guardian newspaper talking about patient priorities in prostate cancer care.
Find out more here https://bit.ly/3QvGUiy and https://bit.ly/3RMWSpu and in today’s Guardian (22/09/2022)
Department of International Trade and Health and Invest Newcastle Visit Accord’s Fawdon Site
We were pleased to welcome John Lownds of the Life Sciences and Chemical Directorate, Department of International Trade and Becky Crow, Health and Life Science Sector Lead at Invest Newcastle) to our Fawdon site last week.
During the visit and factory tour, we were able to demonstrate the tremendous growth in capability and capacity already achieved on site but also the significant potential for future growth sustaining and developing sustainable long term employment within the North East Lifesciences sector.
Jason Barclay, Associate VP Operations, Site Head Fawdon says of the visit: “Both John and Becky were impressed with our people and the facility and also the range of product technologies we are manufacturing and supplying from here in Fawdon.
“Looking forward we are planning to work with both national and local government and agencies to help us on our journey. We have already made contact through Invest Newcastle to find ways to promote our employment offering (including Graduates and Apprentices) across the region.”
#FromFawdon.For Patients Everywhere
Pictured – Jason Barclay, John Lownds, Becky Crow and Ajay Varshney
We employ over 560 #scientists across the world to bring more #medicines to people who need them. It's our mission to make sure that everyone has access to the best possible treatments. And we're always looking for talented people to join our team
Supporting IHP to Make it Better for those in Ukraine and beyond
Over the last six months, our commitment to support IHP our corporate charity partner to provide access to medicines across war torn and disaster struck countries has increased.
As one of their main donors, here is a little sneak peek at what we have contributed to and IHP have delivered so far:
IHP Visit Fawdon
It was a pleasure to welcome our corporate charity partner @IHP to our site at Fawdon recently.
Representatives from International Health Partners highlighted the importance of our partnership, some of the positive case studies our donations have made an impact on and discussed how Accord’s donations make a difference to war torn and disaster struck countries such as Ukraine, Sudan, and many others who rely on essential medicines being donated.
In addition to our people hearing from IHP, representatives from the NGO were also shown around our impressive facilities at Fawdon to gain a better understanding of the manufacturing, packing and logistical elements of our pharmaceutical organisation.
Thank you for visiting Fawdon!
Accord Germany Turns 10
A decade of dedication from our teams in Munich and beyond to achieve this milestone of delivering medicines to patients across Germany.
Thank you to everyone involved in Germany’s journey.
BREAKING NEWS – New Partnership for Oncology Franchise
Prostate cancer is now one of the most commonly diagnosed cancers in the UK, with over 400,000 men living with #prostate cancer in the UK.
Today, via a new in-license partnership that enables us to distribute a new treatment option for men living with hormone-sensitive advanced prostate cancer, we continue to build on our leadership position in #oncology whilst underpinning our commitment to supporting access to medicines for people with #cancer.
We want to say thank you to our talented team that played such a large part in this milestone. Because today, our team really did make it better at Accord.
Ask Accord - Peter Kelly
We kick off a new series of 'Ask Accord' in Chemist+Druggist answering burning questions from pharmacists about the generic and biosimilar medicine industry. This first article answers the age-old question "why do generic medicine prices sometimes spike?" Peter Kelly, Managing Director at Accord has an answer. https://bit.ly/3vqT43I</wbr> #pharmacists
Today we meet our new Associate Vice President for Operations, Fawdon, Jason Barclay and hear what attracted him to Accord.
“Accord is a fast growing organisation and that for me is an attractive proposition at a personal professional level, but also as a deeply passionate and committed adoptive Northumbrian. Accord is a big employer in the region, bringing not just jobs but STEM opportunities to a wide audience and that for me was key to my next role.
“Just a week into the organisation and the role and it is clear that everyone here in Fawdon is dedicated to the ongoing success of the site and there is a real sense of pride and passion to continually grow what we have to offer.
“I will be spending the next few weeks engaging with the teams here in Fawdon and further afield to understand our customer base in more detail and engage with wider stakeholders.
“There has been excellent investment into the site and its facilities, but it is now time to take that further. I am looking forward to delivering a long term, sustainable success story here in the North East and I know the team here are too.”
If you want to join the team and be part of something, we have several vacancies.